SVB Leerink Reiterates Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)
SVB Leerink Reiterates Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating)'s stock had its "outperform" rating reaffirmed by stock analysts at SVB Leerink in a research note issued on Friday, Benzinga reports. They presently have a $160.00 price objective on the biotechnology company's stock. SVB Leerink's price objective points to a potential upside of 22.87% from the stock's previous close.
据Benzinga报道,Sarepta Treateutics(纳斯达克代码:SRPT-GET Rating)的股票分析师在周五发布的一份研究报告中重申了Sarepta Treateutics的股票评级为“跑赢大盘”。他们目前为这家生物技术公司的股票设定了160.00美元的目标价。SVB Leerink的目标价显示,该股可能比前一交易日收盘价上涨22.87%。
Several other analysts have also issued reports on SRPT. BTIG Research boosted their target price on Sarepta Therapeutics from $125.00 to $160.00 and gave the company a "buy" rating in a research note on Thursday, December 22nd. StockNews.com initiated coverage on Sarepta Therapeutics in a research note on Wednesday, October 12th. They issued a "hold" rating on the stock. UBS Group upgraded Sarepta Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the company from $100.00 to $158.00 in a research note on Friday, December 16th. Cowen boosted their target price on Sarepta Therapeutics from $114.00 to $125.00 in a research note on Wednesday, January 11th. Finally, Royal Bank of Canada lowered their target price on Sarepta Therapeutics from $193.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday, November 3rd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $150.14.
其他几位分析师也发布了关于SRPT的报告。BTIG Research在12月22日星期四的一份研究报告中将Sarepta治疗公司的目标价从125.00美元上调至160.00美元,并给予该公司“买入”评级。StockNews.com在10月12日星期三的一份研究报告中启动了对Sarepta治疗公司的报道。他们对该股的评级为“持有”。瑞银集团在周五的一份研究报告中将Sarepta Treeutics的评级从中性上调至买入,并将该公司的目标价从100.00美元上调至158.00美元。考恩在1月11日星期三的一份研究报告中将Sarepta治疗公司的目标价从114.00美元上调至125.00美元。最后,加拿大皇家银行将赛瑞普塔治疗公司的目标价从193.00美元下调至190.00美元,并在11月3日(星期四)的一份研究报告中对该股设定了“跑赢大盘”的评级。三名投资分析师对该股的评级为持有,七名分析师对该股的评级为买入。根据MarketBeat.com的数据,该公司目前的共识评级为“适度买入”,共识目标价为150.14美元。
Sarepta Therapeutics Price Performance
Sarepta治疗公司的价格表现
Shares of SRPT opened at $130.22 on Friday. Sarepta Therapeutics has a 1 year low of $61.28 and a 1 year high of $134.08. The company has a debt-to-equity ratio of 3.58, a current ratio of 4.36 and a quick ratio of 3.99. The company has a market capitalization of $11.43 billion, a price-to-earnings ratio of -15.86 and a beta of 1.04. The business has a 50-day moving average of $121.96 and a 200-day moving average of $110.67.
上周五,SRPT的股价开盘报130.22美元。Sarepta Treeutics的一年低点为61.28美元,一年高位为134.08美元。该公司的债务权益比为3.58,流动比率为4.36,速动比率为3.99。该公司市值为114.3亿美元,市盈率为-15.86倍,贝塔系数为1.04。该业务的50日移动均线切入位在121.96美元,200日移动均线切入位在110.67美元。
Insider Activity at Sarepta Therapeutics
Sarepta治疗公司的内部活动
In related news, Director Stephen Mayo sold 858 shares of the firm's stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $109.92, for a total transaction of $94,311.36. Following the completion of the transaction, the director now owns 6,387 shares of the company's stock, valued at approximately $702,059.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.40% of the stock is owned by corporate insiders.
在相关新闻中,董事斯蒂芬·梅奥在11月17日(星期四)的一笔交易中出售了858股该公司股票。该股以109.92美元的平均价格出售,总成交金额为94311.36美元。交易完成后,董事现在持有该公司6,387股股票,价值约702,059.04美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过这个环节。6.40%的股份由企业内部人士持有。
Hedge Funds Weigh In On Sarepta Therapeutics
对冲基金入股Sarepta Treeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. Harbor Capital Advisors Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter valued at about $296,000. Asset Dedication LLC bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $65,000. Perfromance Wealth Partners LLC bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $207,000. Calton & Associates Inc. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $209,000. Finally, Maryland State Retirement & Pension System bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $828,000. 87.31% of the stock is currently owned by hedge funds and other institutional investors.
一些机构投资者和对冲基金最近调整了对该公司的持股。港湾资本顾问公司在第四季度购买了Sarepta Treeutics的新股份,价值约29.6万美元。资产奉献有限责任公司在第四季度购买了Sarepta治疗公司的新股份,价值约6.5万美元。Performmance Wealth Partners LLC在第四季度购买了Sarepta治疗公司的新股份,价值约20.7万美元。Calton&Associates Inc.在第四季度购买了Sarepta Treeutics的新股,价值约20.9万美元。最后,马里兰州退休和养老金系统在第四季度购买了Sarepta治疗公司的新股份,价值约82.8万美元。87.31%的股票目前由对冲基金和其他机构投资者持有。
Sarepta Therapeutics Company Profile
Sarepta治疗公司简介
(Get Rating)
(获取评级)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
Sarepta治疗公司是一家商业阶段的生物制药公司,专注于发现和开发RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的遗传疗法。它提供ExONDYS 51注射用于治疗Duchenne肌营养不良症(Duchenne)患者,用于治疗Duchenne肌营养不良症(Duchenne)患者,用于治疗Duchenne肌营养不良症(Duchenne)患者;VYONDYS 53用于治疗Duchenne肌营养不良症患者,用于治疗Duchenne病患者,用于治疗Duchenne肌营养不良症患者,可跳过外显子53。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免费获取StockNews.com关于Sarepta治疗(SRPT)的研究报告
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Sarepta治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Sarepta治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。